<DOC>
	<DOC>NCT00151996</DOC>
	<brief_summary>The purpose of this study is to assess the safety and tolerability of administering SPD503 (Guanfacine hydrochloride) with psychostimulants (amphetamine or methylphenidate) for treatment of ADHD in children and adolescents aged 6-17</brief_summary>
	<brief_title>Safety and Tolerability of SPD503 and Psychostimulants in Children and Adolescents Aged 6-17 With Attention-Deficit/Hyperactivity Disorder (ADHD)</brief_title>
	<detailed_description />
	<mesh_term>Disease</mesh_term>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Amphetamine</mesh_term>
	<mesh_term>Methylphenidate</mesh_term>
	<mesh_term>Guanfacine</mesh_term>
	<criteria>Subjects with a primary diagnosis of ADHD Subject on a stable dose of a psychostimulant approved for the treatment of ADHD for at least 1 month, with suboptimal control in the Investigator's opinion Male or nonpregnant female subject who agrees to comply with any applicable contraceptive requirements Subject has current uncontrolled comorbid psychiatric diagnosis (except ODD and mild anxiety) with significant symptoms History of seizure during the last 2 years Subject has any specific cardiac condition or family history of significant cardiac condition Subject is pregnant or lactating</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>